Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients

Yusuke Tsuda, Koichi Ogura, Michiyuki Hakozaki, Kazutaka Kikuta, Keisuke Ae, Hiroyuki Tsuchiya, Shintaro Iwata, Takafumi Ueda, Hirotaka Kawano, Akira Kawai

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies.

METHODS: Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively analyzed.

RESULTS: Data from 29 males and 28 females were collected. Primary tumor sites were the head and neck (7 patients), trunk (35 patients), and extremities (15 patients). The tumors originating in the trunk were significantly associated with a worse OS compared with those originating at the other sites in all patients and those with localized disease (P = 0.020 and P = 0.019, respectively). In patients with localized disease, the tumors originating in the head and neck were significantly associated with better OS and MFS compared with those originating in the trunk (P = 0.024 and P = 0.014, respectively). Positive surgical margin was significantly correlated with the worse LRFS (P = 0.018). Adjuvant chemotherapy exhibited a clear trend toward improved OS when MCS was localized in the trunk or extremities (P = 0.057).

CONCLUSIONS: Adequate surgery is considered to be the mainstay of treatment for localized MCS. Prognosis was different depending on the site of tumor origin.

Original languageEnglish
Pages (from-to)760-767
Number of pages8
JournalJournal of Surgical Oncology
Volume115
Issue number6
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Mesenchymal Chondrosarcoma
Neoplasms
Neck
Extremities
Head
Adjuvant Chemotherapy
Therapeutics

Keywords

  • clinical features
  • mesenchymal chondrosarcoma
  • prognostic factors

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Tsuda, Y., Ogura, K., Hakozaki, M., Kikuta, K., Ae, K., Tsuchiya, H., ... Kawai, A. (2017). Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients. Journal of Surgical Oncology, 115(6), 760-767. https://doi.org/10.1002/jso.24567

Mesenchymal chondrosarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients. / Tsuda, Yusuke; Ogura, Koichi; Hakozaki, Michiyuki; Kikuta, Kazutaka; Ae, Keisuke; Tsuchiya, Hiroyuki; Iwata, Shintaro; Ueda, Takafumi; Kawano, Hirotaka; Kawai, Akira.

In: Journal of Surgical Oncology, Vol. 115, No. 6, 01.05.2017, p. 760-767.

Research output: Contribution to journalArticle

Tsuda, Y, Ogura, K, Hakozaki, M, Kikuta, K, Ae, K, Tsuchiya, H, Iwata, S, Ueda, T, Kawano, H & Kawai, A 2017, 'Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients', Journal of Surgical Oncology, vol. 115, no. 6, pp. 760-767. https://doi.org/10.1002/jso.24567
Tsuda, Yusuke ; Ogura, Koichi ; Hakozaki, Michiyuki ; Kikuta, Kazutaka ; Ae, Keisuke ; Tsuchiya, Hiroyuki ; Iwata, Shintaro ; Ueda, Takafumi ; Kawano, Hirotaka ; Kawai, Akira. / Mesenchymal chondrosarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients. In: Journal of Surgical Oncology. 2017 ; Vol. 115, No. 6. pp. 760-767.
@article{ed9756456d1c4730bdeeac719d4c0394,
title = "Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients",
abstract = "BACKGROUND: This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies.METHODS: Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively analyzed.RESULTS: Data from 29 males and 28 females were collected. Primary tumor sites were the head and neck (7 patients), trunk (35 patients), and extremities (15 patients). The tumors originating in the trunk were significantly associated with a worse OS compared with those originating at the other sites in all patients and those with localized disease (P = 0.020 and P = 0.019, respectively). In patients with localized disease, the tumors originating in the head and neck were significantly associated with better OS and MFS compared with those originating in the trunk (P = 0.024 and P = 0.014, respectively). Positive surgical margin was significantly correlated with the worse LRFS (P = 0.018). Adjuvant chemotherapy exhibited a clear trend toward improved OS when MCS was localized in the trunk or extremities (P = 0.057).CONCLUSIONS: Adequate surgery is considered to be the mainstay of treatment for localized MCS. Prognosis was different depending on the site of tumor origin.",
keywords = "clinical features, mesenchymal chondrosarcoma, prognostic factors",
author = "Yusuke Tsuda and Koichi Ogura and Michiyuki Hakozaki and Kazutaka Kikuta and Keisuke Ae and Hiroyuki Tsuchiya and Shintaro Iwata and Takafumi Ueda and Hirotaka Kawano and Akira Kawai",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/jso.24567",
language = "English",
volume = "115",
pages = "760--767",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Mesenchymal chondrosarcoma

T2 - A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients

AU - Tsuda, Yusuke

AU - Ogura, Koichi

AU - Hakozaki, Michiyuki

AU - Kikuta, Kazutaka

AU - Ae, Keisuke

AU - Tsuchiya, Hiroyuki

AU - Iwata, Shintaro

AU - Ueda, Takafumi

AU - Kawano, Hirotaka

AU - Kawai, Akira

PY - 2017/5/1

Y1 - 2017/5/1

N2 - BACKGROUND: This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies.METHODS: Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively analyzed.RESULTS: Data from 29 males and 28 females were collected. Primary tumor sites were the head and neck (7 patients), trunk (35 patients), and extremities (15 patients). The tumors originating in the trunk were significantly associated with a worse OS compared with those originating at the other sites in all patients and those with localized disease (P = 0.020 and P = 0.019, respectively). In patients with localized disease, the tumors originating in the head and neck were significantly associated with better OS and MFS compared with those originating in the trunk (P = 0.024 and P = 0.014, respectively). Positive surgical margin was significantly correlated with the worse LRFS (P = 0.018). Adjuvant chemotherapy exhibited a clear trend toward improved OS when MCS was localized in the trunk or extremities (P = 0.057).CONCLUSIONS: Adequate surgery is considered to be the mainstay of treatment for localized MCS. Prognosis was different depending on the site of tumor origin.

AB - BACKGROUND: This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies.METHODS: Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively analyzed.RESULTS: Data from 29 males and 28 females were collected. Primary tumor sites were the head and neck (7 patients), trunk (35 patients), and extremities (15 patients). The tumors originating in the trunk were significantly associated with a worse OS compared with those originating at the other sites in all patients and those with localized disease (P = 0.020 and P = 0.019, respectively). In patients with localized disease, the tumors originating in the head and neck were significantly associated with better OS and MFS compared with those originating in the trunk (P = 0.024 and P = 0.014, respectively). Positive surgical margin was significantly correlated with the worse LRFS (P = 0.018). Adjuvant chemotherapy exhibited a clear trend toward improved OS when MCS was localized in the trunk or extremities (P = 0.057).CONCLUSIONS: Adequate surgery is considered to be the mainstay of treatment for localized MCS. Prognosis was different depending on the site of tumor origin.

KW - clinical features

KW - mesenchymal chondrosarcoma

KW - prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=85032161831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032161831&partnerID=8YFLogxK

U2 - 10.1002/jso.24567

DO - 10.1002/jso.24567

M3 - Article

C2 - 29044531

AN - SCOPUS:85032161831

VL - 115

SP - 760

EP - 767

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 6

ER -